Nicole Tay

Nicole Tay

Auto-generated profile, based on publicly available information

Nicole Tay

Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2019 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
AIAlex Ing
Alex Ing
PSPhilipp G. Sämann
Philipp G. Sämann
CCCongying Chu
Congying Chu
NTNicole Tay
Nicole Tay
FBFrancesca Biondo
Francesca Biondo
ICIMAGEN Consortium
IMAGEN Consortium

28 September 2021 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
LKLiubov S. Kalinichenko
Liubov S. Kalinichenko
Christiane MühleChristiane Mühle
Christiane Mühle
TJTianye Jia
Tianye Jia
FAFelix Anderheiden
Felix Anderheiden
MDMaria Datz
Maria Datz
CMChristian P. Müller
Christian P. Müller
Mental disorders are highly comorbid and occur together with physical diseases, which are often considered to arise from separate pathogenic pathways. We observed in alcohol-dependent patients increased serum activity of neutral sphingomyelinase. A genetic association analysis in 456,693 volunteers found associations of haplotypes ofSMPD3coding for NSM-2 (NSM) with alcohol consumption, but also with affective state, and bone mineralisation. Functional analysis in mice showed that NSM controls alcohol consumption, affective behaviour, and their interaction by regulating hippocampal volume, cortical connectivity, and monoaminergic responses. Furthermore, NSM controlled bone–brain communication by enhancing osteocalcin signalling, which can independently supress alcohol consumption and reduce depressive behaviour. Altogether, we identified a single gene source for multiple pathways originating in the brain and bone, which interlink disorders of a mental–physical co-morbidity trias of alcohol abuse—depression/anxiety—bone disorder. Targeting NSM and osteocalcin signalling may, thus, provide a new systems approach in the treatment of a mental–physical co-morbidity trias.

19 November 2019 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
WMWeida Meng
Weida Meng
LSLouise K. Sjöholm
Louise K. Sjöholm
OKOlga Kononenko
Olga Kononenko
NTNicole Tay
Nicole Tay
DZDandan Zhang
Dandan Zhang
YLYun Liu
Yun Liu

20 April 2020 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
TJTian-ye Jia
Tian-ye Jia
AIAlex Ing
Alex Ing
EQErin Burke Quinlan
Erin Burke Quinlan
NTNicole Tay
Nicole Tay
QLQiang Luo
Qiang Luo
ICIMAGEN Consortium
IMAGEN Consortium

10 November 2022 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
RPRoberto Pagano
Roberto Pagano
ASAhmad Salamian
Ahmad Salamian
JZJanusz Zielinski
Janusz Zielinski
ABAnna Beroun
Anna Beroun
MNMaria Nalberczak-Skóra
Maria Nalberczak-Skóra
KRKasia Radwanska
Kasia Radwanska

1 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CFChris Fidyk
Chris Fidyk
SPSerena Popat
Serena Popat
NTNicole Tay
Nicole Tay
LSLuke Smith
Luke Smith
RBRebecca Bowen
Rebecca Bowen
Agnieszka MichaelAgnieszka Michael
Agnieszka Michael
TPS1614 Background: Cancer is the leading contributor of disease burden worldwide, and incidence rates are estimated to rise 47% by 2040. With increasing numbers of people living with cancer, alongside healthcare workforce shortages, current models for cancer monitoring and surveillance are unsustainable. Within the UK’s National Health Service (NHS), this is exacerbated by a rising backlog following the COVID-19 pandemic. Furthermore, a 2020 Macmillan Cancer Support survey showed that current patient information and support is scattered, inaccessible, and poorly personalized. There is an urgent need for effective personalized tools to support cancer patient self-management and data collection to enable healthcare professional (HCP) monitoring and remote follow-up. Methods: A multi-site randomized controlled trial is underway within the NHS to evaluate the implementation of a novel digital oncology platform (Vinehealth) for personalized support. Vinehealth consists of a mobile patient application, integrated wearables data, and a clinician dashboard. The study aims to recruit 180 patients across 8 NHS Trusts diagnosed with (i) colorectal, breast, or lung cancer undergoing adjuvant systemic treatment (chemotherapy +/- targeted therapies) post surgery, or (ii) asymptomatic breast cancer undergoing neoadjuvant treatment. A power calculation was conducted relating to the primary objective demonstrating the efficacy in improvement of QoL in the interventional arm, providing 80% power and at a significance level of 0.05. Enrolled patients will be randomized (1:1) between standard of care (SoC) and interventional arms (SoC plus Vinehealth platform). The main objective is to assess if implementation of Vinehealth improves patients’ quality of life (QoL) compared to SoC based on EQ-5D-5L, EORTC QLQ-C30, and FACT-G (PWB) questionnaires. Secondary objectives include assessing patient compliance with electronic patient-reported outcome (ePRO) data collection and patient self-management of symptoms. The study will further evaluate whether Vinehealth improves the process of care (assessed through medication adherence) and reduces emergency healthcare utilization (including ED/GP visits/admissions and acute oncology hotline use). Questionnaires are completed by all patients at baseline, 6, 12, 18 and 24 weeks. Qualitative interviews will be conducted with a subset of interventional arm patients and HCPs from each NHS Trust to understand engagement with the Vinehealth platform. To our knowledge, this is the first multi-site RCT within the NHS to evaluate the impact of a digital oncology platform on cancer patients’ QoL, ePRO compliance, process of care, and healthcare utilization. The trial is expected to end by September 2023 with results being reported in January 2024. Clinical trial information: ISRCTN44293246 .